Lilly launches Mounjaro in India, beating Novo Nordisk to the market

Eli Lilly launched its diabetes and weight-loss drug Mounjaro in India on March 20, 2025, beating rival Novo Nordisk into a country of more than 1.4 billion people that drugmakers see as a major growth market ^[1]. By late 2025, Mounjaro had become one of the top-selling drugs in India by value, according to the development summary tied to this report.

Lilly priced Mounjaro's lowest doses far below what US patients typically pay. A 2.5 mg vial cost about 3,500 rupees, or roughly $40.54, and a 5 mg vial cost about 4,375 rupees, or about $50.67 ^[1]. A patient taking a weekly 5 mg dose could expect to spend about $200 a month ^[1]. That compares with a US list price of $1,086.37 for a month's supply of Mounjaro, though what American patients actually pay depends heavily on insurance coverage ^[1]. Lilly's Zepbound, the same drug sold in the US for obesity rather than diabetes, has cash prices around $499 a month for some doses ^[1]. An analyst told Reuters that even at Indian prices, a patient on the highest 15 mg dose could still pay close to 700,000 rupees, or about $8,100, a year — a sum he called high for the Indian market ^[1].

Novo Nordisk's competing drug, Wegovy, had already received Indian regulatory approval when Lilly launched Mounjaro, but Novo had not set a launch date as of March 2025 ^[1]. Novo's India team had reportedly pushed the company's global leadership to launch Wegovy in 2025 rather than wait until a planned 2026 rollout ^[1]. Novo went on to launch Wegovy in India on June 24, 2025, three months after Mounjaro arrived ^[2]. Lilly followed in June with regulatory approval for a Mounjaro KwikPen, a pre-filled injector offering six dose strengths from 2.5 mg to 15 mg, giving the company more ways to compete as Novo entered the market ^[2].

Both companies face a crowded field of Indian generic drugmakers preparing their own versions of these medicines. Semaglutide, the active ingredient in Wegovy and Ozempic, is expected to lose patent protection in India in 2026, and companies including Sun Pharma, Cipla, Dr. Reddy's, Lupin, Biocon, Zydus Lifesciences, Natco, Mankind Pharma and Aurobindo Pharma are developing or planning generic versions ^[1][2]. Sun Pharma, India's largest drugmaker by revenue, is also developing its own original GLP-1 treatment called utreglutide, which it expects to launch within four to five years ^[2]. Analysts have pointed to a global GLP-1 market estimated to be worth $150 billion over the next decade as the reason so many companies are racing to enter ^[1].

Why it matters for patients

For US patients, the India launch is mostly a signal about how differently these drugs are priced around the world. Lilly told Reuters that prices in different countries cannot be directly compared because healthcare systems, economies and reimbursement policies vary so much ^[1]. Still, the gap between roughly $40 to $50 a vial in India and a US list price above $1,000 a month illustrates how much of the US price reflects the American insurance and reimbursement system rather than the cost of making the drug.

The India rollout does not change what US patients pay or how they access Mounjaround, Zepbound, Ozempic or Wegovy today. It also does not mean cheaper generic versions of these drugs will be available in the US any time soon; the semaglutide patent expiration referenced in the sources applies to India and other emerging markets, not to US patent protections ^[1][2].

What happens next

Novo Nordisk launched Wegovy in India on June 24, 2025 ^[2]. Lilly's Mounjaro KwikPen, covering six dose strengths, was approved by India's drug regulator on the same day ^[2]. Sun Pharma has said it expects to launch its own GLP-1 drug, utreglutide, in four to five years ^[2]. Indian generic drugmakers are expected to seek approval for copies of semaglutide once its patent lapses in India in 2026 ^[1][2], though none of the sources give a specific date for any generic launch.